

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/698,106	10/31/2003	Karla M. Robotti	10030204-1 8960	
7590 03/20/2006			EXAMINER	
AGILENT TECHNOLOGIES, INC.			BRADLEY, CHRISTINA	
Legal Departme	nt, DL429			
Intellectual Property Administration			ART UNIT	PAPER NUMBER
P.O. Box 7599			1654	
Loveland, CO 80537-0599			DATE MAILED: 03/20/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/698,106	ROBOTTI, KARLA M.				
Office Action Summary	Examiner	Art Unit				
	Christina M. Bradley	1654				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS,						
WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	ely filed the mailing date of this communication. (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 10/31	<u>/2003</u> .					
2a) This action is <b>FINAL</b> . 2b) This	1) This action is <b>FINAL</b> . 2b) This action is non-final.					
	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-37</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) ☐ Claim(s) is/are objected to.	la attana na mata a sa at					
8) Claim(s) <u>1-37</u> are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
and the shadhed detailed entire detail for a list of the defined depice flot rederved.						
Attach monat(n)						
Attachment(s)  1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date.						
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal Pa 6) Other:	itent Application (PTO-152)				
S. Robert and Trademost Office						

Application/Control Number: 10/698,106 Page 2

Art Unit: 1654

### **DETAILED ACTION**

#### Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - Claims 1-21, drawn to a method for separating phosphorylated peptides from a mixture comprising phosphorylated and unphosphorylated peptides, classified in class 530, subclass 344.
  - II. Claims 22-29, drawn to peptides bound to a capture ligand, classified in class 530, subclass 300.
  - III. Claims 30-37, drawn to kits for separating phosphorylated peptides from a mixture comprising phosphorylated and unphosphorylated peptides, classified in class 210, subclass 656.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I and II are patentably distinct. The method in Group I is not required to produce the product in Group II. A peptide can be directly linked to a capture ligand without reacting the peptides with the first resin described in the method of Claim I. In addition, the product in Group II is not required to use the method in Group I. The method in Group I requires the use of resins and coupling and cleavage reagents.

Although a mixture of phosphorylated and unphosphorylated peptides can be separated by this method, the use of the method does not require that the peptides be previously linked to capture ligands and a different substrate altogether can be applied such as a

Art Unit: 1654

protein or any other phosphorylated polymer. Therefore, neither invention would render the other obvious. Furthermore, a different search is required for each group.

Page 3

- 3. Inventions I and III are related as process of use and product. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the method for separating phosphorylated and unphosphorylated peptides could be used with a different set of resins comprising different functional groups for peptide coupling.

  Alternatively, phosphorylated and unphosphorylated peptides can be separated by an entirely different method such as metal affinity chromatography. In addition, the kit could be used to separate phosphorylated from unphosphorylated proteins, or any other phosphorylated polymer from its underivatized form provided that said polymer lacks other functional groups that would interfere with the purification scheme. Therefore, neither invention would render the other obvious. Furthermore, a different search is required for each group.
- 4. The peptide linked to a capture ligand of Group II and the kit for separating phosphorylated and unphosphorylated peptides of Group III are related. The related inventions are distinct if the inventions as claimed do not overlap in scope, i.e., are mutually exclusive; the inventions as claimed are not obvious variants; and the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect. See MPEP 806.05(j). In the

Page 4

Art Unit: 1654

instant case, the peptide claims do not overlap the scope of the kit claims and vice versa as evidenced by the distinct structures and functions of the claimed inventions. The peptide comprises a polymer of amino acids linked by peptide bonds, possible phosphorylated sites as well as a covalent link to a capture ligand. In contrast the kit comprises resins and reagents necessary for coupling peptides to the resins, protecting functional groups and cleaving linkages. The capture ligand bound peptide and the kit are functionally distinct from each other because one is a modified polymer of amino acids and the other a collection of reagents and resins useful for peptide purification. Additionally, the peptide and the kit are not obvious variants of each other based on the distinct structures and functions of each as noted above. Lastly, the peptide and the kit have materially different functions as noted above. Thus, by virtue of the different structures and functions of the inventions of Groups II and III, these related inventions are patentably distinct. Furthermore, a different search is required for each group.

Because these inventions are independent or distinct for the reasons given above, have acquired a separate status in the art in view of their different classification, and require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

## Notice of Possible Rejoinder

5. The examiner has required restriction between product and process claims.
Where applicant elects claims directed to the product, and a product claim is
subsequently found allowable, withdrawn process claims that depend from or otherwise

Art Unit: 1654

include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Page 5

6. In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Application/Control Number: 10/698,106 Page 6

Art Unit: 1654

7. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

#### Conclusion

- 8. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.
- 9. The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.
- 10. Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.
- 11. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Art Unit: 1654

remaining in the application. Any amendment of inventorship must be accompanied by

a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

12. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Christina Bradley whose telephone number is (571) 272-

9044. The examiner can normally be reached on Monday-Friday, 8:30-5.

13. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Bruce Campell can be reached on (571) 272-0974. The fax phone number

for the organization where this application or proceeding is assigned is 571-273-8300.

14. Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

cmb

BRUCE R. CAMPELL, PH.D. SUPERVISORY PATENT EXAMINER

Brue Campell

Page 7

TECHNOLOGY CENTER 1600